Sadra Medical is dedicated to developing innovative new therapies for the treatment of aortic valve disease. By developing minimally invasive alternatives to traditional surgical valve replacement, the company seeks to help improve patient care and make valve replacement possible for broader range of patients. Treatment of aortic valve disease remains a significant and growing unmet clinical need. As many as 3 million people in U.S. have aortic valve stenosis; however, only a small percentage of those are treated with the current standard of care, valve replacement during open-heart surgery using cardiopulmonary bypass. By developing a highly effective aortic valve replacement that is designed to reduce the risks and morbidity associated with open surgical valve replacement, Sadra Medical seeks to provide a therapeutic option for patients who are not being treated today.

Financials

Date Type Amount Investors Valuation
10/23/06 Series B 19M Onset Ventures, Pequot Ventures, Schroder Ventures, Yellowstone Capital Unknown

People

Lori Adels (Acting VP of Quality & Regulatory)

Amr Salahieh (CTO)

David Milne (Board Member)

Juliet Tammenoms Bakker (Board Member)

Fred Khosravi (Board Member)

View more details about all 7 people at Sadra Medical

News

Sadra Medical raises $30M for aortic valve replacement

May 8, 2009 1:24 am

July 9-10, 2013 San Francisco, CA Tickets On Sale Now Sadra Medical, which is developing a procedure to replace the… Continue reading ⟩

Life sciences briefing: Friday, Oct. 19, 2007

October 19, 2007 3:06 pm

Featured companies: DirectFlow, Direvo, Indigo Biosystems, MacroGenics Direct Flow raises $27M for heart-valve implants — Santa Rosa, Calif.-based Direct Flow… Continue reading ⟩

Valve disease treatment co., Sadra, raises $9M

October 23, 2006 5:07 pm

July 9-10, 2013 San Francisco, CA Tickets On Sale Now Sadra Medical, a Campbell company developing therapies for aortic valve… Continue reading ⟩